Lymph node stromal cells (LNSC) are essential for providing and maintaining peripheral self-tolerance of potentially autoreactive cells. In type 1 diabetes, proinsulin-specific CD8+ T cells, escaping central and peripheral tolerance, contribute to β-cell destruction. Using G9Cα−/−CD8+ T cells specific for proinsulin, we studied the mechanisms by which LNSC regulate low-avidity autoreactive cells in the NOD mouse model of type 1 diabetes. Whereas MHC-matched NOD-LNSC significantly reduced G9Cα−/−CD8+ T-cell cytotoxicity and dendritic cell–induced proliferation, they failed to sufficiently regulate T cells stimulated by anti-CD3/CD28. In contrast, non-MHC–matched, control C57BL/6 mouse LNSC suppressed T-cell receptor engagement by anti-CD3/CD28 via MHC-independent mechanisms. This C57BL/6-LNSC suppression was maintained even after removal of the LNSC, demonstrating a direct effect of LNSC on T cells, modifying antigen sensitivity and effector function. Thus, our results suggest that a loss of NOD-LNSC MHC-independent suppressive mechanisms may contribute to diabetes development.

CD8+ T cells are critical for type 1 diabetes development, responding to islet-specific antigens, including proinsulin (PI), and mediating β-cell death. The G9C8 CD8+ T-cell clone was isolated from pancreatic islets of NOD mice (1); it recognizes PI β-chain amino acids 15-23 restricted by MHC class I Kd (2) and induces rapid diabetes after adoptive transfer (1,3,4). T-cell receptor (TCR)-transgenic G9Cα−/− mice are a valuable source of clonal G9C8 CD8+ T cells (hereafter called G9Cα−/−CD8+ T cells) to study selection, activation, and regulation of low-avidity autoreactive cells (3,5,6).

Thymic expression of peripheral tissue antigens (PTAs) has been well described to provide negative selection of developing T cells. However, low-avidity T cells that recognize self-antigen can escape thymic selection and persist in the periphery. Lymph node stromal cells (LNSC) also express PTAs and can induce T-cell tolerance (713), providing a potential therapeutic target for peripheral interventions. PI expressed in pancreatic lymph nodes (LNs) is regulated by deformed epidermal autoregulatory factor 1 (Deaf1) (12,14,15). Various LNSC subsets express Deaf1 (11) and Ins2 (16,17) in murine models. We have previously reported that LNSC can suppress G9Cα−/−CD8+ T cells, dependent upon PI expression (5). However, LNSC regulatory mechanisms are poorly described. In this brief report, we identify distinct MHC-dependent and -independent regulatory pathways in LNSC and that the latter is reduced in NOD mice.

Mice

All procedures and protocols were approved by the U.K. Home Office. NOD-PI2tg mice, expressing PI2 on the MHC class II promoter, were provided by Professors L. Harrison and A. Lew (18). TCR-transgenic G9Cα−/− mice were generated as previously described (3). C57BL/6 (B6), NOD, and MHC-congenic C57BL/6-H2g7 (B6.H2g7) mice were bred in-house. Mice were maintained in specific pathogen-free microisolators or scantainers at Cardiff University. Male and female mice were used in all experiments.

Isolation of LNSC

LNSC were prepared from NOD, B6, or B6.H2g7 mice, as previously described (5,19), by pooling the cervical, axillary, brachial, inguinal, popliteal, and pancreatic LNs from six to eight mice. Analyses of individual LN sets required 20–25 mice/group. LNSC were expanded for 7–10 days in RPMI 1640 with 10% FBS at 37°C with 5% CO2.

LNSC Conditioning of CD8+ T Cells

LNSC were isolated and expanded as described above, treated with 0.25% trypsin-EDTA (Sigma-Aldrich) for 5 min at 37°C, and harvested. LNSC were seeded at 105 cells/well in six-well plates for 24–48 h. Splenic G9Cα−/−CD8+ T cells were isolated using CD8a microbeads (Miltenyi Biotec), and 106 cells/well were added to LNSC cultures. The CD8+ T cells were collected after 48 h of coculture, with or without LNSC, and investigated for effects of LNSC exposure on cytotoxicity and proliferation (Fig. 1A). To determine the contribution of transforming growth factor-β1 (TGF-β1), a blocking antibody (clone 19D8; BioLegend) was added each day to cocultures (Fig. 1B). Additionally, 10 pg/mL recombinant TGF-β1 (rTGF-β1) (R&D Systems) was added to CD8+ T cells cultured alone, prior to, or added directly to the cytotoxicity assays (Fig. 1C).

Figure 1

Experimental design schematics. A: LNSC were isolated and expanded in vitro. CD8+ T cells were isolated from G9Cα−/− mice and cocultured with LNSC or alone for 48 h for preconditioning. Supernatants from the coculture were collected. Freshly isolated (nonpreconditioned) G9Cα−/−CD8+ T cells and P815 cytotoxic target cells were assayed in the transferred supernatant from LNSC/T-cell cultures or T cells cultured alone (control). LNSC-conditioned G9Cα−/−CD8+ T cells were stimulated with: 1) peptide-loaded P815 cytotoxic targets without LNSC, 2) NOD.PI2tg-DCs with (continued) or without (post) LNSC, or 3) anti-CD3/CD28 Dynabeads with (continued) or without (post) LNSC. Cytotoxicity or proliferation and activation were assessed to determine the effect of LNSC preconditioning on CD8+ T cell function compared with control CD8+ T cells cultured alone. B: CD8+ T cells were isolated from G9Cα−/− mice and cocultured with LNSC. Anti–TGF-β1 blocking antibody (0.2 µg/mL) or no antibody (control) was added each day of the 2-day culture. Supernatants from the coculture were collected. Freshly isolated (nonconditioned) G9Cα−/−CD8+ T cells and P815 cytotoxic target cells were assayed in the transferred supernatant with or without anti–TGF-β1. G9Cα−/−CD8+ T cells conditioned with LNSC and anti–TGF-β1 were stimulated with peptide-loaded P815 cytotoxic targets. C: CD8+ T cells were isolated from G9Cα−/− mice and cultured for 2 days with rTGF-β1 (10 pg/mL) or without rTGF-β1 (control) added each day. Preconditioned cells were stimulated with peptide-loaded P815 cytotoxic targets. Cytotoxicity of freshly isolated G9Cα−/−CD8+ T cells was assessed with rTGF-β1 (10 pg/mL or 0 pg/mL control) present during incubation with P815 targets. hr, hour.

Figure 1

Experimental design schematics. A: LNSC were isolated and expanded in vitro. CD8+ T cells were isolated from G9Cα−/− mice and cocultured with LNSC or alone for 48 h for preconditioning. Supernatants from the coculture were collected. Freshly isolated (nonpreconditioned) G9Cα−/−CD8+ T cells and P815 cytotoxic target cells were assayed in the transferred supernatant from LNSC/T-cell cultures or T cells cultured alone (control). LNSC-conditioned G9Cα−/−CD8+ T cells were stimulated with: 1) peptide-loaded P815 cytotoxic targets without LNSC, 2) NOD.PI2tg-DCs with (continued) or without (post) LNSC, or 3) anti-CD3/CD28 Dynabeads with (continued) or without (post) LNSC. Cytotoxicity or proliferation and activation were assessed to determine the effect of LNSC preconditioning on CD8+ T cell function compared with control CD8+ T cells cultured alone. B: CD8+ T cells were isolated from G9Cα−/− mice and cocultured with LNSC. Anti–TGF-β1 blocking antibody (0.2 µg/mL) or no antibody (control) was added each day of the 2-day culture. Supernatants from the coculture were collected. Freshly isolated (nonconditioned) G9Cα−/−CD8+ T cells and P815 cytotoxic target cells were assayed in the transferred supernatant with or without anti–TGF-β1. G9Cα−/−CD8+ T cells conditioned with LNSC and anti–TGF-β1 were stimulated with peptide-loaded P815 cytotoxic targets. C: CD8+ T cells were isolated from G9Cα−/− mice and cultured for 2 days with rTGF-β1 (10 pg/mL) or without rTGF-β1 (control) added each day. Preconditioned cells were stimulated with peptide-loaded P815 cytotoxic targets. Cytotoxicity of freshly isolated G9Cα−/−CD8+ T cells was assessed with rTGF-β1 (10 pg/mL or 0 pg/mL control) present during incubation with P815 targets. hr, hour.

Close modal

CD8+ T-Cell Cytotoxicity After Preconditioning With LNSC

After 48-h conditioning, G9Cα−/−CD8+ T cells were incubated with 5 μg/mL InsB15-23 peptide-loaded P815 cells (mastocytoma cell line expressing MHC class I Kd) for 16 h (Fig. 1B, top). Freshly isolated (nonconditioned) G9Cα−/− T cells were suspended in supernatants from the 48-h cultures of LNSC alone, CD8+ T cells, or LNSC/CD8+ T cells and incubated with peptide-loaded P815 targets labeled with PKH-26 (Sigma-Aldrich) (Fig. 1B, bottom). Specific lysis of PKH+ P815 targets detected by TO-PRO-3 (Molecular Probes) staining was calculated using flow cytometry (5,20).

Proliferation of T Cells

NOD-PI2tg bone marrow–derived dendritic cells (DCs) were prepared as previously described (5). G9Cα−/−CD8+ T cells were purified using MACS CD8+ T-cell Isolation Kit II (Miltenyi Biotec). Lipopolysaccharide-activated DCs and 0.5 µmol/L carboxyfluorescein diacetate succinimidyl ester (CFDA-SE)–labeled T cells were cultured with LNSC (5) or separated by a transwell with 0.4-µm pore membrane (Corning). Proliferation and activation after 72 h were evaluated by flow cytometry using BD LSRFortessa and analyzed with FlowJo (Tree Star, Inc.). LNSC-conditioned G9Cα−/−CD8+ T cells were labeled with 0.5 µmol/L carboxyfluorescein diacetate (Invitrogen) and then stimulated with 10 μL/106 cells of anti-CD3/CD28 Dynabeads (Thermo Fisher Scientific) or with NOD-PI2tg-DCs in the continued presence of or after the removal of LNSC (Fig. 1A). After 72 h, G9Cα−/−CD8+ T cells were stained with anti-CD8, anti-Vβ6, and live/dead exclusion (eBioscience). Cells were labeled with anti–T-bet and anti-Zap70 (BioLegend) after fixation/permeabilization (eBioscience) following the manufacturer’s directions. Cytokine synthesis of interferon-γ (IFN-γ), MIP-1β, interleukin-10, and free-active TGF-β1 was measured using a LEGENDplex premixed kit (BioLegend) (standard curve range 2–10,000 pg/mL), following the manufacturer’s directions, and analyzed with LEGENDplex V8.0.

Statistics

Data are presented as mean ± SD. One-way ANOVA with multiple-comparisons test was used to compare experimental groups to controls using Prism V6.07 (GraphPad Software). P < 0.05 was considered significant.

Data and Resource Availability

The data sets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Pre-exposure to LNSC Reduces Cytolytic Potential of PI-Specific G9Cα−/−CD8+ T Cells

We incubated G9Cα−/−CD8+ T cells with LNSC to determine if LNSC could directly affect T-cell activation and whether the effect was maintained after LNSC removal. G9Cα−/−CD8+ T cells were cultured alone or with LNSC for 48 h (Fig. 1A). Cytotoxicity, without LNSC present (Fig. 2), was assessed. Specific lysis of targets by cytotoxic T lymphocytes previously cultured with NOD-LNSC (Fig. 2A, left), B6-LNSC (Fig. 2A, second panel from left), B6.H2g7-LNSC (Fig. 2A, third panel from left), or alone (Fig. 2A, right) was compared. Preincubation with either Kd-MHC–matched (NOD and B6.H2g7) or Kb-MHC–mismatched (B6) LNSC reduced the subsequent cytotoxicity of G9Cα−/−CD8+ T cells (Fig. 2B), with the greatest reduction after NOD-LNSC exposure.

Figure 2

LNSC reduction of cytotoxic potential of PI-specific G9Cα−/−CD8+ T cells. Splenic G9Cα−/−CD8+ T cells were incubated for 48 h alone or with LNSC isolated from NOD, B6, or B6.H2g7 mice. Conditioned CD8+ T cells were collected and incubated with 5 μg/mL InsB15-23 peptide-loaded P815 targets. After 16 h, specific lysis was determined by flow cytometry. A: Representative dot plots of P815 targets after incubation with CD8+ T cells preincubated with NOD-LNSC (left panel), B6-LNSC (second panel from left), B6.H2g7-LNSC (second panel from right), or control T cells alone (right panel) (range 58–81% dead in independent experiments). B: Specific lysis was calculated as a percent of control CD8+ T cells cultured alone (horizontal line at 100%). Preconditioning with all LN sets significantly reduced cytotoxicity. Statistical difference compared with control is shown on the graph. Additional comparisons: NOD vs. B6.H2g7, P < 0.03; NOD vs. B6, P = 0.15; and B6 vs. B6.H2g7, P = 0.3. C: Supernatants from the 48-h incubation of LNSC and CD8+ T cells were collected for supernatant transfer. Freshly isolated splenic G9Cα−/−CD8+ T cells and peptide-loaded targets were incubated for 16 h in the transferred supernatant. Specific lysis was calculated as a percent of lysis in control supernatant from T cells cultured alone for 48 h (horizontal line at 100%). Supernatants from each of the cultures containing LNSC and T cells significantly suppressed lysis compared with control supernatant taken from G9Cα−/−CD8+ T cells alone. Statistical difference compared with control is shown. There were no statistical differences when comparing supernatants from G9Cα−/−CD8+ T cells cultured with different LNSC sources (NOD vs. B6, NOD vs. B6.H2g7, and B6 vs. B6.H2g7). D: Supernatants were analyzed with BioLegend LEGENDplex for free-active TGF-β1 synthesis, with a standard curve range of 2–10,000 pg/mL. TGF-β1 production was increased when LNSC and T cells were cultured together. There was no detectable TGF-β1 when T cells or LNSC (data not shown) were cultured alone. E: Anti–TGF-β1 blocking antibody (0.2 µg/mL) or rTGF-β1 (10 pg/mL) was added to LNSC/T-cell cocultures to determine contributions of TGF-β1 to subsequent suppression of cytotoxicity. F: After coculture, T-cell cytotoxicity was assessed in the presence of anti–TGF-β1 (0.2 µg/mL) or rTGF-β1 (10 pg/mL) (untreated, same as in E). Freshly isolated G9Cα−/−CD8+ T-cell cytotoxicity was measured using supernatants harvested from LNSC/T-cell cocultures with anti–TGF-β1 (0.2 µg/mL) present in the coculture (G) or added directly to the cytotoxicity assay (H). Supernatants from T cells cultured alone were used as control (set at 100%). Mean ± SD of three to four independent experiments performed in duplicate.

Figure 2

LNSC reduction of cytotoxic potential of PI-specific G9Cα−/−CD8+ T cells. Splenic G9Cα−/−CD8+ T cells were incubated for 48 h alone or with LNSC isolated from NOD, B6, or B6.H2g7 mice. Conditioned CD8+ T cells were collected and incubated with 5 μg/mL InsB15-23 peptide-loaded P815 targets. After 16 h, specific lysis was determined by flow cytometry. A: Representative dot plots of P815 targets after incubation with CD8+ T cells preincubated with NOD-LNSC (left panel), B6-LNSC (second panel from left), B6.H2g7-LNSC (second panel from right), or control T cells alone (right panel) (range 58–81% dead in independent experiments). B: Specific lysis was calculated as a percent of control CD8+ T cells cultured alone (horizontal line at 100%). Preconditioning with all LN sets significantly reduced cytotoxicity. Statistical difference compared with control is shown on the graph. Additional comparisons: NOD vs. B6.H2g7, P < 0.03; NOD vs. B6, P = 0.15; and B6 vs. B6.H2g7, P = 0.3. C: Supernatants from the 48-h incubation of LNSC and CD8+ T cells were collected for supernatant transfer. Freshly isolated splenic G9Cα−/−CD8+ T cells and peptide-loaded targets were incubated for 16 h in the transferred supernatant. Specific lysis was calculated as a percent of lysis in control supernatant from T cells cultured alone for 48 h (horizontal line at 100%). Supernatants from each of the cultures containing LNSC and T cells significantly suppressed lysis compared with control supernatant taken from G9Cα−/−CD8+ T cells alone. Statistical difference compared with control is shown. There were no statistical differences when comparing supernatants from G9Cα−/−CD8+ T cells cultured with different LNSC sources (NOD vs. B6, NOD vs. B6.H2g7, and B6 vs. B6.H2g7). D: Supernatants were analyzed with BioLegend LEGENDplex for free-active TGF-β1 synthesis, with a standard curve range of 2–10,000 pg/mL. TGF-β1 production was increased when LNSC and T cells were cultured together. There was no detectable TGF-β1 when T cells or LNSC (data not shown) were cultured alone. E: Anti–TGF-β1 blocking antibody (0.2 µg/mL) or rTGF-β1 (10 pg/mL) was added to LNSC/T-cell cocultures to determine contributions of TGF-β1 to subsequent suppression of cytotoxicity. F: After coculture, T-cell cytotoxicity was assessed in the presence of anti–TGF-β1 (0.2 µg/mL) or rTGF-β1 (10 pg/mL) (untreated, same as in E). Freshly isolated G9Cα−/−CD8+ T-cell cytotoxicity was measured using supernatants harvested from LNSC/T-cell cocultures with anti–TGF-β1 (0.2 µg/mL) present in the coculture (G) or added directly to the cytotoxicity assay (H). Supernatants from T cells cultured alone were used as control (set at 100%). Mean ± SD of three to four independent experiments performed in duplicate.

Close modal

LNSC/T-Cell Contact Produces Soluble Suppressive Factors

We tested the influence of supernatant harvested from the LNSC/T-cell precultures on cytotoxic function of freshly isolated splenic G9Cα−/−CD8+ T cells (Fig. 1A). Control cytotoxicity in each experiment was conducted in supernatant from T cells incubated alone for 48 h (baseline 100%). Specific lysis was significantly reduced by supernatants from LNSC/T-cell precultures (Fig. 2C), with NOD-LNSC supernatants again inducing the most significant suppression. The supernatants collected from LNSC that were incubated alone did not confer suppression, suggesting that LNSC/T-cell contact is required to release a soluble factor capable of inhibiting cytotoxicity. Analyses of supernatants identified TGF-β1 only in samples collected from LNSC/T-cell precultures (Fig. 2D), but not in supernatants from cultures of T cells or LNSC alone (data not shown). No interleukin-10 was detected (data not shown). This supports the hypothesis that LNSC have a direct effect on CD8+ T cells and regulate subsequent T-cell activation, even when LNSC are no longer present. Blocking TGF-β1 with anti–TGF-β1 during LNSC/T-cell cultures (Fig. 1B) neither prevented subsequent inhibition of preconditioned CD8+ T-cell cytotoxicity (Fig. 2E), nor did it override the suppressed phenotype resulting from LNSC pre-exposure (Fig. 2F). Anti–TGF-β1 blocking during the LNSC/T-cell preculture did not prevent subsequent suppression by the supernatants (Fig. 2G). Anti–TGF-β1 added together with the supernatants in the cytotoxic assay partially reduced the suppressive capacity of supernatants, particularly the B6.H2g7/T-cell culture supernatant (Fig. 2H). Addition of rTGF-β1 to T cells cultured alone (Fig. 1C) did not confer subsequent suppression (Fig. 2E), although rTGF-β1 suppressed cytotoxicity directly in the cytotoxic assays (Fig. 2F), suggesting that preconditioned LNSC-mediated suppression is TGF-β1 independent.

NOD-LNSC Suppress Antigen Stimulation of CD8+ T Cells

We have previously demonstrated that pancreatic LNSC induce peptide/MHC-dependent suppression of G9Cα−/−CD8+ T-cell proliferation (5). NOD-LNSC derived from draining (pancreatic) and nondraining (inguinal and cervical) sites all inhibited NOD-PI2tg-DC–induced T-cell proliferation (Supplementary Fig. 1A), suggesting that PI is systemically expressed in LNs as part of a tolerogenic self-antigen repertoire. Transwell separation of the G9Cα−/−CD8+ T cells eliminated the suppressive effect of MHC-matched NOD-LNSC, supporting a contact-dependent mechanism (Supplementary Fig. 1B). Preincubation with LNSC did not induce suppression; rather, the continued presence of Kd-matched NOD-LNSC was required for reduced CD8+ T-cell proliferation (Fig. 3A and B). There was no difference in the production of IFN-γ (Fig. 3C) or MIP-1β (Fig. 3D) with LNSC. Analyses of T-bet (Fig. 3E and Supplementary Fig. 2A) and Zap70 (Fig. 3F and Supplementary Fig. 2B) expression did not show any statistically significant modification associated with LNSC exposure or suppressed proliferation.

Figure 3

Contact-dependent LNSC suppression of DC-stimulated proliferation of CD8+ T cells. G9Cα−/−CD8+ T cells were collected after 48-h incubation alone (control) or in the presence of LNSC from NOD, B6, or B6.H2g7 mice. The preconditioned T cells were then stimulated with NOD-PI2tg-DCs either after the removal of LNSC (post) or in the continued presence of LNSC (cont.). A: Representative histograms of CFDA-SE dilution, with calculation of percent of divided conditioned G9Cα−/−CD8+ T cells, following NOD-PI2tg-DC stimulation. B: Proliferation is represented as a percentage of control T cells cultured alone and then stimulated with DCs for 3 days in the absence of LNSC (range 24–45% divided in independent experiments) (horizontal line). Continued presence of NOD- or B6.H2g7-LNSC was required for suppression of proliferation. Synthesis of IFN-γ (C) and MIP-1β (D) after 3 days of NOD-PI2tg-DC stimulation was measured using BioLegend LEGENDplex. There were no significant changes associated with LNSC presence. Intracellular expression of T-bet (E) and Zap70 (F) was evaluated after 3 days of stimulation. Percent positive cells is represented as a percent of control T cells cultured alone (horizontal line). LNSC exposure did not affect T-bet or Zap70 expression following DC stimulation. Mean ± SD of two to four independent experiments.

Figure 3

Contact-dependent LNSC suppression of DC-stimulated proliferation of CD8+ T cells. G9Cα−/−CD8+ T cells were collected after 48-h incubation alone (control) or in the presence of LNSC from NOD, B6, or B6.H2g7 mice. The preconditioned T cells were then stimulated with NOD-PI2tg-DCs either after the removal of LNSC (post) or in the continued presence of LNSC (cont.). A: Representative histograms of CFDA-SE dilution, with calculation of percent of divided conditioned G9Cα−/−CD8+ T cells, following NOD-PI2tg-DC stimulation. B: Proliferation is represented as a percentage of control T cells cultured alone and then stimulated with DCs for 3 days in the absence of LNSC (range 24–45% divided in independent experiments) (horizontal line). Continued presence of NOD- or B6.H2g7-LNSC was required for suppression of proliferation. Synthesis of IFN-γ (C) and MIP-1β (D) after 3 days of NOD-PI2tg-DC stimulation was measured using BioLegend LEGENDplex. There were no significant changes associated with LNSC presence. Intracellular expression of T-bet (E) and Zap70 (F) was evaluated after 3 days of stimulation. Percent positive cells is represented as a percent of control T cells cultured alone (horizontal line). LNSC exposure did not affect T-bet or Zap70 expression following DC stimulation. Mean ± SD of two to four independent experiments.

Close modal

NOD-LNSC Did Not Suppress Antigen-Independent TCR Stimulation

We were surprised to find B6-LNSC reduction of cytotoxicity (Fig. 2) but not DC-stimulated proliferation (Fig. 3), suggesting that MHC-independent mechanisms also play a role in driving LNSC-mediated suppression. To delineate the effects of peptide/MHC-dependent (NOD/B6.H2g7) and -independent (B6) mechanisms, as well as investigate whether there were strain differences (NOD vs. B6 genetic background), G9Cα−/−CD8+ T cells were cultured with LNSC for 48 h. LNSC-conditioned CD8+ T cells were then stimulated with anti-CD3/CD28 Dynabeads (Fig. 1A), following removal of the LNSC or in the continued presence of LNSC for 3 days, to provide robust antigen-independent stimulation. Proliferation (Fig. 4A and B) and TCR-Vβ6 (Fig. 4C), and CD8 (Fig. 4D) expression were analyzed by flow cytometry. NOD-LNSC only suppressed proliferation when continuously present (Fig. 4A and B, in the continued presence of LNSC); however, B6- and B6.H2g7-LNSC induced more significant suppression when T cells were stimulated by direct TCR engagement using anti-CD3/CD28 (Fig. 4B). Reduced proliferation was associated with decreased upregulation of surface TCR and CD8 (Fig. 4C and D, respectively) compared with CD8+ T cells not exposed to LNSC. Synthesis of IFN-γ and MIP-1β was significantly reduced, particularly when LNSC were present, further demonstrating a loss of proinflammatory signals (Fig. 4E and F, respectively).

Figure 4

LNSC suppression of CD8+ T-cell proliferation and TCR expression is associated with decreased T-bet and Zap70 expression. G9Cα−/−CD8+ T cells were collected after 48-h incubation alone or in the presence of LNSC from NOD, B6, or B6.H2g7 mice. The preconditioned T cells were then stimulated for 3 days with anti-CD3/CD28 Dynabeads after the removal of LNSC (post) or in the continued presence of LNSC (cont.). A: Representative histograms of CFDA-SE dilution, with calculation of percent divided and proliferation index of conditioned G9Cα−/−CD8+ T cells, following anti-CD3/CD28 antibody stimulation. B: The percentage of cells that had divided was standardized to control (T cells cultured alone, range 81–92% divided in independent experiments, horizontal line), set as 100%. G9Cα−/−CD8+ T cells conditioned with B6- or B6.H2g7-LNSC showed the most significant inhibition of proliferation. Vβ6 (C) and CD8 (D) expression was measured following 3 days of anti-CD3/CD28 antibody Dynabead stimulation, either following removal of LNSC (post) or in the continued presence of the LNSC (cont.). Fold change was calculated as an increase/decrease of mean fluorescence intensity (MFI) relative to unstimulated T cells (dashed line). The continued presence of B6- or B6.H2g7-LNSC prevented upregulation of surface Vβ6 (C) and CD8 (D) expression compared with G9Cα−/−CD8+ T cells in the absence of LNSC. Synthesis of IFN-γ (E) and MIP-1β (F) after 3 days of Dynabead stimulation was measured using BioLegend LEGENDplex. LNSC exposure significantly reduced the amount of IFN-γ (E) and MIP-1β (F) present in culture supernatants compared with G9Cα−/−CD8+ T cells in the absence of LNSC. Mean ± SD of three to four independent experiments. Intracellular expression of T-bet (G) and Zap70 (H) was evaluated after stimulation of LNSC-conditioned CD8+ T cells by anti-CD3/CD28 Dynabeads. Percentage of positive cells is represented as a percentage of control T cells cultured alone (horizontal line). B6- and B6.H2g7-LNSC significantly reduced T-bet expression and continued exposure reduced Zap70 expression. Continued NOD-LNSC presence was required to significantly reduce T-bet expression; however, no significant reduction of Zap70 was found. Mean ± SD of two to three independent experiments.

Figure 4

LNSC suppression of CD8+ T-cell proliferation and TCR expression is associated with decreased T-bet and Zap70 expression. G9Cα−/−CD8+ T cells were collected after 48-h incubation alone or in the presence of LNSC from NOD, B6, or B6.H2g7 mice. The preconditioned T cells were then stimulated for 3 days with anti-CD3/CD28 Dynabeads after the removal of LNSC (post) or in the continued presence of LNSC (cont.). A: Representative histograms of CFDA-SE dilution, with calculation of percent divided and proliferation index of conditioned G9Cα−/−CD8+ T cells, following anti-CD3/CD28 antibody stimulation. B: The percentage of cells that had divided was standardized to control (T cells cultured alone, range 81–92% divided in independent experiments, horizontal line), set as 100%. G9Cα−/−CD8+ T cells conditioned with B6- or B6.H2g7-LNSC showed the most significant inhibition of proliferation. Vβ6 (C) and CD8 (D) expression was measured following 3 days of anti-CD3/CD28 antibody Dynabead stimulation, either following removal of LNSC (post) or in the continued presence of the LNSC (cont.). Fold change was calculated as an increase/decrease of mean fluorescence intensity (MFI) relative to unstimulated T cells (dashed line). The continued presence of B6- or B6.H2g7-LNSC prevented upregulation of surface Vβ6 (C) and CD8 (D) expression compared with G9Cα−/−CD8+ T cells in the absence of LNSC. Synthesis of IFN-γ (E) and MIP-1β (F) after 3 days of Dynabead stimulation was measured using BioLegend LEGENDplex. LNSC exposure significantly reduced the amount of IFN-γ (E) and MIP-1β (F) present in culture supernatants compared with G9Cα−/−CD8+ T cells in the absence of LNSC. Mean ± SD of three to four independent experiments. Intracellular expression of T-bet (G) and Zap70 (H) was evaluated after stimulation of LNSC-conditioned CD8+ T cells by anti-CD3/CD28 Dynabeads. Percentage of positive cells is represented as a percentage of control T cells cultured alone (horizontal line). B6- and B6.H2g7-LNSC significantly reduced T-bet expression and continued exposure reduced Zap70 expression. Continued NOD-LNSC presence was required to significantly reduce T-bet expression; however, no significant reduction of Zap70 was found. Mean ± SD of two to three independent experiments.

Close modal

Antigen-Independent Regulation Associated With Reduced T-bet and Zap70 Expression

Exposure to B6- or B6.H2g7-LNSC significantly reduced G9Cα−/−CD8+ T-cell intracellular expression of T-bet (Fig. 4G and Supplementary Fig. 3A) after anti-CD3/CD28 antibody stimulation, irrespective of whether LNSC were still present in the culture; Zap70 was only reduced in continuous culture (Fig. 4H and Supplementary Fig. 3B). These data suggest that there are distinct signaling pathways involved in direct, non–antigen-specific TCR engagement (anti-CD3/CD28) compared with low-avidity peptide/MHC stimulation and that there are strain differences in regulation of these pathways. However, in contrast to the B6-LNSC, NOD-LNSC only reduced T-bet in continuous culture and did not significantly reduce Zap70 in G9Cα−/−CD8+ T cells, suggesting a defect in NOD-LNSC MHC-independent suppressive mechanisms.

We have identified distinct MHC-dependent and -independent mechanisms of peripheral regulation by LNSC, resulting in decreased proliferation and effector function of PI-specific CD8+ T cells. Not only do LNSC have critical structural and chemotactic roles, but they also modulate and regulate T-cell responses (5,79,11,2123), through expression of PTAs (8,11,15,24). We have previously demonstrated that pancreatic LNSC suppress PI-specific G9Cα−/−CD8+ T cells (5). In this study, we found that nondraining LNSC also induce contact-dependent suppression (Supplementary Fig. 1A). Furthermore, LNSC regulation includes both MHC-dependent and -independent components. These data suggest that LN PI expression is widespread and regulates T-cell activity, supporting a role for PI in peripheral self-tolerance. Studies in other transgenic mouse models suggested that tolerance mechanisms were intrinsic to LNSC (79). The identification of LNSC endogenously expressing PTAs confirmed this essential compartment for maintaining T-cell tolerance and immune homeostasis (12,13). Nichols et al. (13) found that lymphatic endothelial cells expressing tyrosinase directly presented antigen and induced deletion of high-affinity CD8+ T cells. However, low-avidity tyrosinase-specific cells persist in the periphery and contribute to restricting melanoma outgrowth (25,26). Low-avidity recognition of PI/MHC class I Kd allows G9Cα−/−CD8+ T cells to escape both thymic selection and peripheral deletion, as these cells persist in the periphery (4,5). Therefore, continued regulation of these cells is required to prevent aberrant activation and autoreactivity.

We have shown that the effect of LNSC-induced tolerance persists. LNSC conditioning of G9Cα−/−CD8+ T cells (Fig. 1A) significantly reduced subsequent cytolytic potential (Fig. 2), suggesting an intrinsic modification to T cells after LNSC contact. However, supernatants from LNSC/T-cell culture also reduced cytotoxicity of nonconditioned effectors (Fig. 2C), which provides evidence that LNSC/T-cell contact induces suppressive soluble factors, including TGF-β1 (Fig. 2D). Surprisingly, we observed that the MHC-mismatched Kb-expressing B6-LNSC suppressed cytotoxicity (Fig. 2A and B). Supernatants from B6-LNSC/CD8+ T-cell incubation also suppressed cytotoxicity (Fig. 2C) and generated TGF-β1 (Fig. 2D), although to a lesser degree than NOD-LNSC/T-cell supernatants. Blocking TGF-β1 (Fig. 1B) did not fully restore cytotoxicity (Fig. 2E–H), nor did the addition of rTGF-β1 during preculture (Fig. 1C) provide subsequent suppression (Fig. 2E). These results suggest that while regulatory, TGF-β1 alone did not induce the intrinsic modification to T-cell function during LNSC/T-cell precultures. These data suggest that MHC-independent mechanisms also contribute to overall regulation of T cells when preconditioned by LNSC.

We investigated the suppressive mechanisms intrinsic to LNSC by stimulating LNSC-conditioned G9Cα−/−CD8+ T cells using antigen-specific NOD-PI2tg-DCs or non–antigen-specific anti-CD3/CD28 Dynabeads (Fig. 1A) and observed differential effects. LNSC from NOD and B6.H2g7suppressed antigen-specific NOD-PI2tg-DC-stimulation of G9Cα−/−CD8+ T cells (Fig. 3A and B). B6- and B6.H2g7-LNSC suppressed anti-CD3/CD28 T-cell proliferation and activation much more than NOD-LNSC (Fig. 4). Furthermore, suppression induced by exposure to B6- and B6.H2g7-LNSC was observed even when LNSC were removed; however, continued presence of NOD-LNSC was required for suppression (Fig. 4, following removal of LNSC vs. in the continued presence of the LNSC), suggesting NOD-LNSC did not induce sufficient intrinsic modifications to the T-cell phenotype. These data highlight differential pathways when regulating robust (anti-CD3/CD28) versus weak (insulin antigen) activation. MHC-dependent suppressive mechanisms reduced antigen-dependent cytotoxicity (Fig. 2) and proliferation (Fig. 3) but did not suppress the effects of direct TCR engagement (Fig. 4). The MHC-independent suppression was also associated with decreased expression of T-bet and Zap70 (Fig. 4 and Supplementary Figs. 2 and 3). However, T-bet expression was not affected by low-avidity antigen stimulation, suggesting different pathways are used. Further work is needed to elucidate the differential signaling and regulation of these pathways associated with signal strength and antigen specificity.

Finally, our work suggests NOD-LNSC are less able to provide MHC-independent suppression of antibody stimulation and that there is a defect in this regulatory compartment associated with autoimmunity. Most studies have used models of high-affinity antigen when addressing peripheral T-cell regulation and deletional tolerance; the fate of low-avidity cells is less known but has important implications for regulating autoreactive T cells and monitoring outcomes of therapeutic interventions.

This article contains supplementary material online at https://doi.org/10.2337/figshare.13146209.

Acknowledgments. The authors thank members of the Joint Biological Services of Cardiff University for animal care and Len Harrison and Andrew Lew, from the Walter and Eliza Hall Institute of Medical Research (Parkville, Victoria, Australia), for the gift of NOD-PI2tg mice. The authors also thank Daniel S. Thayer (Swansea University, Swansea, U.K.) for editorial assistance.

Funding. The work was supported by a postdoctoral fellowship from JDRF (3-PDF-2014-211-A-N to T.C.T.) and funding from the Medical Research Council (U.K.) (MR/K021141/1 to F.S.W.).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. T.C.T. carried out experiments and analyzed the data. S.J.H. assisted with experimental design. J.D. and J.A.P. assisted with experiments. T.C.T and F.S.W. conceived the project and wrote the manuscript. T.C.T., S.J.H., L.W., and F.S.W. edited the manuscript. F.S.W. is the guarantor of this work, and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

1.
Wong
FS
,
Visintin
I
,
Wen
L
,
Flavell
RA
,
Janeway
CA
 Jr
.
CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells
.
J Exp Med
1996
;
183
:
67
76
2.
Wong
FS
,
Karttunen
J
,
Dumont
C
, et al
.
Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library
.
Nat Med
1999
;
5
:
1026
1031
3.
Wong
FS
,
Siew
LK
,
Scott
G
, et al
.
Activation of insulin-reactive CD8 T-cells for development of autoimmune diabetes
.
Diabetes
2009
;
58
:
1156
1164
4.
Wong
FS
,
Moustakas
AK
,
Wen
L
,
Papadopoulos
GK
,
Janeway
CA
 Jr
.
Analysis of structure and function relationships of an autoantigenic peptide of insulin bound to H-2K(d) that stimulates CD8 T cells in insulin-dependent diabetes mellitus
.
Proc Natl Acad Sci U S A
2002
;
99
:
5551
5556
5.
Thayer
TC
,
Pearson
JA
,
De Leenheer
E
, et al
.
Peripheral proinsulin expression controls low-avidity proinsulin-reactive CD8 T cells in type 1 diabetes
.
Diabetes
2016
;
65
:
3429
3439
6.
Pearson
JA
,
Thayer
TC
,
McLaren
JE
, et al
.
Proinsulin expression shapes the TCR repertoire but fails to control the development of low-avidity insulin-reactive CD8+ T cells
.
Diabetes
2016
;
65
:
1679
1689
7.
Magnusson
FC
,
Liblau
RS
,
von Boehmer
H
, et al
.
Direct presentation of antigen by lymph node stromal cells protects against CD8 T-cell-mediated intestinal autoimmunity
.
Gastroenterology
2008
;
134
:
1028
1037
8.
Lee
JW
,
Epardaud
M
,
Sun
J
, et al
.
Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self
.
Nat Immunol
2007
;
8
:
181
190
9.
Gardner
JM
,
Devoss
JJ
,
Friedman
RS
, et al
.
Deletional tolerance mediated by extrathymic Aire-expressing cells
.
Science
2008
;
321
:
843
847
10.
Cohen
JN
,
Guidi
CJ
,
Tewalt
EF
, et al
.
Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation
.
J Exp Med
2010
;
207
:
681
688
11.
Fletcher
AL
,
Lukacs-Kornek
V
,
Reynoso
ED
, et al
.
Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions
.
J Exp Med
2010
;
207
:
689
697
12.
Yip
L
,
Su
L
,
Sheng
D
, et al
.
Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes
.
Nat Immunol
2009
;
10
:
1026
1033
13.
Nichols
LA
,
Chen
Y
,
Colella
TA
,
Bennett
CL
,
Clausen
BE
,
Engelhard
VH
.
Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes
.
J Immunol
2007
;
179
:
993
1003
14.
Yip
L
,
Fuhlbrigge
R
,
Taylor
C
, et al
.
Inflammation and hyperglycemia mediate Deaf1 splicing in the pancreatic lymph nodes via distinct pathways during type 1 diabetes
.
Diabetes
2015
;
64
:
604
617
15.
Yip
L
,
Creusot
RJ
,
Pager
CT
,
Sarnow
P
,
Fathman
CG
.
Reduced DEAF1 function during type 1 diabetes inhibits translation in lymph node stromal cells by suppressing Eif4g3
.
J Mol Cell Biol
2013
;
5
:
99
110
16.
Rodda
LB
,
Lu
E
,
Bennett
ML
, et al
.
Single-cell RNA sequencing of lymph node stromal cells reveals niche-associated heterogeneity
.
Immunity
2018
;
48
:
1014
1028.e6
17.
Pezoldt
J
,
Pasztoi
M
,
Zou
M
, et al
.
Neonatally imprinted stromal cell subsets induce tolerogenic dendritic cells in mesenteric lymph nodes
.
Nat Commun
2018
;
9
:
3903
18.
French
MB
,
Allison
J
,
Cram
DS
, et al
.
Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice
.
Diabetes
1997
;
46
:
34
39
19.
Fletcher
AL
,
Malhotra
D
,
Acton
SE
, et al
.
Reproducible isolation of lymph node stromal cells reveals site-dependent differences in fibroblastic reticular cells
.
Front Immunol
2011
;
2
:
35
20.
Höppner
M
,
Luhm
J
,
Schlenke
P
,
Koritke
P
,
Frohn
C
.
A flow-cytometry based cytotoxicity assay using stained effector cells in combination with native target cells
.
J Immunol Methods
2002
;
267
:
157
163
21.
Fletcher
AL
,
Malhotra
D
,
Turley
SJ
.
Lymph node stroma broaden the peripheral tolerance paradigm
.
Trends Immunol
2011
;
32
:
12
18
22.
Lukacs-Kornek
V
,
Malhotra
D
,
Fletcher
AL
, et al
.
Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes
.
Nat Immunol
2011
;
12
:
1096
1104
23.
Siegert
S
,
Huang
HY
,
Yang
CY
, et al
.
Fibroblastic reticular cells from lymph nodes attenuate T cell expansion by producing nitric oxide
.
PLoS One
2011
;
6
:
e27618
24.
Hirosue
S
,
Dubrot
J
.
Modes of antigen presentation by lymph node stromal cells and their immunological implications
.
Front Immunol
2015
;
6
:
446
25.
Mullins
DW
,
Bullock
TN
,
Colella
TA
,
Robila
VV
,
Engelhard
VH
.
Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice
.
J Immunol
2001
;
167
:
4853
4860
26.
Colella
TA
,
Bullock
TN
,
Russell
LB
, et al
.
Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy
.
J Exp Med
2000
;
191
:
1221
1232
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.